ArticleBreast cancer research : BCR2025
Missense variants in PRKCD: elucidating their potential association with breast cancer.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PRKCD Orchestrates Sevoflurane-Induced Cognitive Dysfunction in Aged Rats by Regulating PINK1/PRKN Mitophagy Pathway.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMissense single-nucleotide polymorphisms (SNPs) in various genetic pathways can lead to the development of breast cancer. Protein kinase C delta (PRKCD) is involved in various important cellular pathways, and its altered expression has been identified in different cancers. Genetic alteration in this gene can be involved in cancer onset and progression. To date, there are no studies performed to elucidate the role of PRKCD missense variants in the development of breast cancer. Therefore, this study aims to identify the association of pathogenic missense SNPs in PRKCD with breast cancer.
methodsThe missense variants of PRKCD were retrieved from the Ensembl and dbSNP databases. Missense variants were analysed through various computational tools, and four variants of PRKCD rs1703806197 (T/C), rs782555227 (G/A), rs1703449438 (T/C), and rs1575535582 (T/G) were selected from the data. The genotype analysis for these variants was performed for 360 breast cancer patients and 363 healthy controls. Statistical association of variants with breast cancer clinical features was determined through chi-square/Fisher's exact test with a significant P value ≤ 0.05 using GraphPad Prism 8.0 software.
resultsGenotype analysis of PRKCD variants showed that missense SNPs rs782555227 (G/A), rs1703449438 (T/C), and rs1575535582 (T/G) were associated with breast cancer (P value < 0.05). Furthermore, genotypes in these SNPs were also found to be associated with various clinical features of breast cancer patients. Genotypes AG, TC, and TT in variants rs782555227, rs1703449438, and rs1575535582, respectively, were associated with breast cancer metastasis. While genotype AG of variant rs782555227 was also found to be associated with menopausal status and hereditary breast cancer. Moreover, genotype TT in variant rs1575535582 was associated with BRCA1 positive status among the breast cancer patients.
conclusionThe present study identified for the first time the association of specific PRKCD missense variants with breast cancer. These variants could be developed into possible genetic markers for the diagnosis of breast cancer at an early stage; however, further validation studies with a multiethnic large cohort size are required. Furthermore, functional studies of these variants will also aid in attaining insight into the molecular mechanisms through which these missense variants are involved in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.